Capricor Therapeutics Inc Share Price Nasdaq
Stocks
US14070B1017
Biotechnology & Medical Research
| Market Cap | 37Cr 31Cr 29Cr 27Cr 50Cr 3.5TCr 51Cr 346.29Cr 135.04Cr 1.76TCr 137.31Cr 134.33Cr 5.81TCr | P/E 2026 * |
-2.83x | P/E 2027 * | -3.8x |
|---|---|---|---|---|---|
| Enterprise Value | 37Cr 31Cr 29Cr 27Cr 50Cr 3.5TCr 51Cr 346.29Cr 135.04Cr 1.76TCr 137.31Cr 134.33Cr 5.81TCr | EV / Sales 2026 * |
23.1x | EV / Sales 2027 * | 8.46x |
| Free-Float |
90.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| 1 day | +10.01% |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 20/11/2013 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 01/01/2018 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 13/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 01/11/2013 |
David Musket
BRD | Director/Board Member | 68 | 20/11/2013 |
George Dunbar
BRD | Director/Board Member | 79 | 20/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.01% | -11.80% | - | - | 37Cr | |
| -4.31% | -2.14% | +65.79% | +103.90% | 7.21TCr | |
| -4.19% | +1.05% | +46.47% | +85.53% | 6.59TCr | |
| -4.19% | +21.60% | +6.02% | -6.43% | 2.93TCr | |
| -1.28% | -3.23% | -3.23% | +466.26% | 2.75TCr | |
| -4.71% | +7.67% | +47.63% | +18.25% | 2.67TCr | |
| -1.81% | +0.38% | +34.14% | -18.33% | 2.01TCr | |
| +5.36% | -1.67% | +270.18% | +415.10% | 1.82TCr | |
| -2.79% | +0.48% | +12.09% | +562.03% | 1.64TCr | |
| +0.97% | +4.30% | +43.98% | +150.90% | 1.34TCr | |
| Average | -0.70% | +8.55% | +58.12% | +197.47% | 3.22TCr | |
| Weighted average by Cap. | -2.90% | +8.78% | +53.75% | +154.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.58Cr 1.36Cr 1.27Cr 1.16Cr 2.18Cr 151.38Cr 2.21Cr 15Cr 5.84Cr 76Cr 5.94Cr 5.81Cr 251.53Cr | 4.32Cr 3.7Cr 3.47Cr 3.17Cr 5.95Cr 413.69Cr 6.03Cr 41Cr 16Cr 207.81Cr 16Cr 16Cr 687.36Cr |
| Net income | -13Cr -11Cr -10Cr -9.47Cr -18Cr -1.24TCr -18Cr -122.26Cr -48Cr -620.56Cr -48Cr -47Cr -2.05TCr | -9.94Cr -8.51Cr -7.96Cr -7.29Cr -14Cr -950.7Cr -14Cr -94Cr -37Cr -477.58Cr -37Cr -36Cr -1.58TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
